type 2 diabetes
Conditions
Interventions
twice daily ultra-long acting insulin plus ultra-rapid insulin injection
Sponsors
Department of Endocrinology and Metabolism, Nagoya City West Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.type 2 diabetes patients who were prescribed premixed insulin twice daily for more than 8 weeks 2.patients whose glycated hemoglobin level (NGSP) are between 6.5 and 10.0% 3.patients whose age are more than 20 years old 4.patients who can understand informed consent
Exclusion criteria
Exclusion criteria: 1.patients who need insulin therapy newly during this study 2.patients who have allergy for insulin glargine or glulisine 3.patients who had suffered from severe ketosis and diabetic coma or pre-coma 4.patients with serious infection, inflammation, or injury pre- or post- operative state 5.patients who are pregnant, hope to be pregnant, or are in lactation period 6.patients had suffered from drug-induced muscle disorder 7.drug abuser or heavy alcohol drinker
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in HbA1c level Decrease in casual blood glucose level | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of hypoglycemia Frequency of hyperglycemia Change in body weight Change in convenience to switch to ultra-long acting insulin plus ultra-rapid insulin | — |
Countries
Japan
Contacts
Public ContactRyosuke Kimura
Nagoya City West Medical Center Endocrinology and Metabolism
Outcome results
None listed